© 1999 by European Society of Cardiology
First worldwide clinical experience with a new dual chamber implantable cardioverter defibrillator
Advantages and complications
Department of Cardiology, J.W. Goethe University Frankfurt, Germany; *Department of Cardiology, Georg-August University Göttingen, Germany
AIMS: The need for physiological pacing and for improving the ability to discriminate atrial from ventricular tachy-arrhythmias has prompted the development of dual chamber implantable cardioverter/defibrillators (ICDs).
METHODS: Fifty-two patients were implanted with a newly developed dual-chamber ICD providing rate-responsive physiological pacing (Ventak AV II DR). The device possesses two new arrhythmia detection algorithms (‘atrial fibrillation rate threshold’ and ‘ventricular to atrial rate relationship’) in addition to commonly used features such as ‘onset’ and ‘stability’. During implantation, the atrial and ventricular lead impedances and pacing thresholds were determined together with the defibrillation threshold. Prior to discharge, attempts were made to induce both atrial and ventricular tachyarrhythmias in order to test those new detection criteria. All patients were followed for at least 3 months.
RESULTS: The device was successfully implanted in all 52 patients. Placement of the atrial lead was successful in 50/52 patients (96%; P-wave 3·2±1·4 mV; impedance 576±123 |gQ; atrial pacing threshold 1·2±0·9 V). Prior to discharge, 32 episodes of atrial fibrillation (AF) alone, 38 episodes of AF with ventricular fibrillation and 10 episodes of AF with monomorphic ventricular tachycardia were induced in 33/50 patients (66%) and all were appropriately classified by the detection algorithm. During the 3 months follow-up, 12 patients (23%) had appropriate and successful therapies for ventricular arrhythmias, while four patients (8%) experienced inappropriate ICD therapies. Although all these episodes were detected correctly as supraventricular arrhythmias by the device, therapy was delivered because of incorrect or incomplete programming. In all cases reprogramming of the device resolved the problem.
CONCLUSION: Implantation of dual chamber ICDs is feasible and appears to improve discrimination of supraventricular from ventricular tachyarrhythmias. In addition, patients with tachyarrhythmias and concomitant bradyarrhythmias may benefit from simultaneous physiological pacing. However, implantation and follow-up of such patients should be performed at experienced centres since both surgical handling and programming of these devices is more difficult and complex than conventional ICDs.
Key Words: Implantable cardioverter/defibrillator, sudden cardiac death, dual chamber pacing, atrial fibrillation, discrimination of atrial and ventricular arrhythmias, inappropriate ICD shock
Correspondence: Stefan H. Hohnloser, MD, FACC, FESC, J.W. Goethe University, Department of Internal Medicine, Division of Cardiology, Theodor-Stern-Kai 7, D-60596 Frankfurt, Germany.
[1] Garrat CJ. A new evidence base for implantable cardioverter defibrillator therapy. Eur Heart J 1998; 19: 189–191.
[2] Calkins H, Brinker J, Veltri EP. Clinical interactions between pacemakers and automatic implantable cardioverter-defibrillators. J Am Coll Cardiol 1990; 16: 666–673.[Abstract]
[3] Echt DS, Armstrong K, Schmidt P. Clinical experience, complications, and survival in 70 patients with the automatic implantable cardioverter/defibrillator. Circulation 1985; 71: 289–296.
[4] Higgins SL, Williams SK, Pak JP. Indications for implantation of a dual-chamber pacemaker combined with an implantable cardioverter-defibrillator. Am J Cardiol 1998; 81: 1360–1362.[CrossRef][Web of Science][Medline]
[5] Sticherling C, Klingenheben T, Skupin M. Combined therapy with transvenous cardioverter/defibrillator and antibradycardia pacemaker systems. Z Kardiol 1997; 86: 105–112.[Medline]
[6] Sticherling C, Klingenheben T, Cameron D, Hohnloser SH. for the Worldwide 7221 ICD investigators. First worldwide clinical experience with a new down-sized active can implantable cardioverter defibrillator in 162 consecutive patients. PACE 1998; 21: 1778–1783.
[7] Weber M, Block M, Brunn J. Inadequate therapies with implantable cardioverter-defibrillators — incidence, etiology, predictive factors and preventive strategies. Z Kardiol 1996; 85: 809–819.[Web of Science][Medline]
[8] Schmitt C, Montero M, Melichercik J. Significance of supra-ventricular tachyarrhythmias in patients with implanted pacing cardioverter defibrillators. PACE 1994; 17: 295–302.
[9] Grimm W, Flores BF, Marchlinski FE. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. PACE 1992; 15: 1667–1673.
[10] Sticherling C, Klingènheben T, Hohnloser SH. An unusual cause of ICD shock. PACE 1997; 20: 2265–2267.
[11] Pinski SL and Fahy GJ. The proarrhythmic potential of implantable cardioverter-defibrillators. Circulation 1995; 92: 1651–1664.
[12] Olson WH, Bardy GH, Mehra R. Onset and stability for ventricular tachyarrhythmia detection in an implantable cardioverter-defibrillator. Computers in Cardiology 1987; New York, NY IEEE Press 92: pp. 167–170.
[13] Higgins SL, Lee RS, Kramer RL. Stability: an ICD detection criterion for discriminating atrial fibrillation from ventricular tachycardia. J Cardiovasc Electrophysiol 1995; 6: 1081–1088.[CrossRef][Web of Science][Medline]
[14] Neuzner J, Pitschner HF, Schlepper M. Programmable VT detection enhancements in implantable cardioverter defibrillator therapy. PACE 1995; 18: 539–547.
[15] Schaumann A, von zur Muehlen F, Gonska BD. Enhanced detection criteria in implantable cardioverter-defibrillators to avoid inappropriate therapy. Am J Cardiol 1996; 78: 42–50.[Web of Science][Medline]
[16] Klingenheben T, Sticherling C, Skupin M. Intracardiac QRS electrogram width — a new arrhythmia detection feature for implantable cardioverter defibrillators. PACE 1998; 21: 1609–1617.
[17] Swerdlow CD, Chen PS, Kass RM. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994; 23: 1342–1355.[Abstract]
[18] Swerdlow CD, Ahern T, Chen PS. Underdetection of ventricular tachycardia by algorithms to enhance specificity in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol 1994; 24: 416–424.[Abstract]
[19] Chiang CM, Jenkins JM, DiCarlo LA. The value of rate regularity and multiplicity measures to detect ventricular tachycardia in the presence of atrial fibrillation or flutter. PACE 1994; 17: 1503–1508.
[20] LeCarpentier GL, Baga JJ, Yang H. Differentiation of sinus tachycardia from ventricular tachycardia with 1:1 ventriculoatrial conduction in dual chamber implantable cardioverter defibrillators: feasibility of a criterion based on the atrioventricular interval. PACE 1994; 17: 1818–1831.
[21] Korte T, Jung W, Wolpert C. A new classification algorithm for discrimination of ventricular from supra-ventricular tachycardia in a dual chamber implantable cardioverter defibrillator. J Cardiovasc Electrophysiol 1998; 9: 70–73.[Web of Science][Medline]
[23] Cohen TJ, Chien WW, Lurie KG. Implantable cardioverter defibrillator proarrhythmia: case report and review of the literature. PACE 1991; 14: 1326–1329.
[24] PCD Investigator Group. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoractomy: an international multicenter study. J Am Coll Cardiol 1994; 23: 1521–1530.[Abstract]
[25] Blanck Z, Niazi I, Axtell K. Feasibility of concomitant implantation of permanent transvenous pacemaker and defibrillator systems. Am J Cardiol 1994; 74: 1249–1253.[CrossRef][Web of Science][Medline]
[26] Haffajee C, Casavant D, Desai P. Combined third-generation implantable cardioverter defibrillator with permanent unipolar pacemakers: preliminary observations. PACE 1996; 19: 136–142.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A.M.J. Theuns, A. P. J. Klootwijk, D. M. Goedhart, and L. J.L.M. Jordaens Prevention of inappropriate therapy in implantable cardioverter-defibrillators: Results of a prospective, randomized study of tachyarrhythmia detection algorithms J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2362 - 2367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Quesada, J.ús Almendral, F. Arribas, R. Ricci, C. Wolpert, P. Adragao, E. Cobo, X. Navarro, and on behalf DATAS investigators The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator Europace, January 1, 2004; 6(2): 142 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Aliot, Rém. Nitzsché, and A. Ripart Arrhythmia detection by dual-chamber implantable cardioverter defibrillators: A review of current algorithms Europace, January 1, 2004; 6(4): 273 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Theuns, A. P. Klootwijk, G. P. Kimman, T. Szili-Torok, J. R. T. C. Roelandt, and L. Jordaens Initial clinical experience with a new arrhythmia detection algorithm in dual chamber implantable cardioverter defibrillators Europace, January 1, 2001; 3(3): 181 - 186. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||